Achievwin
★★  

US,
2023-10-02 22:34
(435 d 16:24 ago)

Posting: # 23729
Views: 4,715
 

 Carry over and statistical adjustment in BE computations [General Sta­tis­tics]

Post reply
If the forum can throw some light on the addressing following points on carry-over.
what I am trying to understand is how to answer - Unequal carryover (between Test and RLD) effect on potential inflation of Type-1 error and bias in the BE conclusions"
  1. How to measure carry-over (any particular PK parameters or in vitro measures?)
  2. How to assess equal or unequal carryover?
  3. Differences in 1st order or other order carry-over
  4. Is there a cut-off to call negligible carry-over
  5. What are the statistical tests to call it a unequal carry-over or no un-equal carry-over.
  6. How to factor or apply any corrections of observed carry-over in BE and RSABE calculations?
I realize these are loaded questions but any true insight that gets buying by EMA or FDA is much appreciated.
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-10-02 23:06
(435 d 15:52 ago)

@ Achievwin
Posting: # 23730
Views: 4,084
 

 Carry-over → 🚮

Post reply
Hi Achevwin,

please delete carry-over from your vocabulary.
Statistically irrelevant and not required acc. to any guideline (FDA, EMA, WHO, ICH). See this article for details.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
Achievwin
★★  

US,
2023-10-03 14:13
(435 d 00:45 ago)

@ Helmut
Posting: # 23731
Views: 4,104
 

 Carry-over → 🚮

Post reply
Hi Helmut:

❝ please delete carry-over from your vocabulary.


Good point...... but CRLs won't leave you without these questions.... somehow regulators seems to be obsessed with that borderline "Carry-over"

Regards,

Achivewin
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-10-03 14:48
(435 d 00:10 ago)

@ Achievwin
Posting: # 23732
Views: 3,985
 

 Carry-over → 🚮

Post reply
Hi Achivewin,

❝ somehow regulators seems to be obsessed with that borderline "Carry-over"


Against obsession consider psychotherapy or hire an exorcist you trust. :-D
Seriously: Point them to the relevant guidance(s). Give the number of the page.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
dshah
★★  

India,
2023-10-03 18:34
(434 d 20:24 ago)

@ Achievwin
Posting: # 23734
Views: 4,029
 

 Carry-over

Post reply
Dear Achivewin!

❝ Good point...... but CRLs won't leave you without these questions.... somehow regulators seems to be obsessed with that borderline "Carry-over"

How many % of subjects had carryover? If its more than 5% of Cmax, generally the exclusion criteria cover it so that subject is not considered for statistical evaluation. If more than 20% subject has carry over effect (more than 5%Cmax value), than an investigation would be needed but this indicates that washout period was insufficient.
Regards,
Divyen
 
Achievwin
★★  

US,
2023-10-03 22:33
(434 d 16:24 ago)

@ dshah
Posting: # 23736
Views: 3,989
 

 Carry-over

Post reply
Dear Divyan and Helmut:

Whether we like it or not this question keep popping, can you both or anyone answer my questions above (I have views but I want to hear what other alternatives are there - my views align mostly with Helmut view but.... regulators are regulators)

I am struggling with the basic question how to quantify carry-over? and for some products that <5% of Cmax rule is not applied (this is a news for me)

Thanks a lot

AchievWin
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-10-04 10:31
(434 d 04:27 ago)

@ Achievwin
Posting: # 23737
Views: 3,944
 

 Carry-over

Post reply
Hi AchievWin,

❝ Whether we like it or not this question keep popping, can you both or anyone answer my questions above (I have views but I want to hear what other alternatives are there - my views align mostly with Helmut view but.... regulators are regulators)


Again, tell regulators to follow their own guidances. Be polite, if you can.

❝ I am struggling with the basic question how to quantify carry-over?


After a dose we know only one thing for sure:
The concentration is not zero.1


A good part of Stephen Senn’s textbook2 can be understood as an essay against carryover in the model.

If you are really interested in the behavior of the drug/formulation, you could only try PK modeling. Good luck. Even if you succeed, then what? Subtract the estimated concentration-time course of previous period(s) from the observed ones to get the ‘true’ concentrations? No regulator would accept that.

See there (Case 1, slides 4–7). I subtracted the fitted concentrations and presented it as a supportive analysis (after some subjects with pre-dose concentrations in higher periods we amended the SAP). Luckily the total (between- + within-subject) variability was low. The German agency accepted the study based on the data of the first period evaluated as a parallel design (new primary analysis; we crossed fingers). The study passed but it was a close shave.
BTW, with the current ≤5% Cmax rule evaluation as a crossover would have been not be a problem…

❝ and for some products that <5% of Cmax rule is not applied (this is a news for me)


Are you talking about endogenous compounds? Nasty beasts.

  1. Harold Boxenbaum at: Analytical Methods Validation: Bioavailability, Bioequivalence and Pharma­co­ki­netic Studies. (Crystal City I Con­fe­rence). Arlington, VA. December 3–5, 1990.
  2. Senn S. Cross-over Trials in Clinical Research. Chichester: Wiley; 2nd ed. 2002. ISBN: 978-0-471-49653-3.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
Achievwin
★★  

US,
2023-10-04 18:38
(433 d 20:20 ago)

@ Helmut
Posting: # 23741
Views: 3,959
 

 Carry-over

Post reply

❝ Are you talking about endogenous compounds? Nasty beasts.


No, someone said "5% Cmax rule of pre-dose doesn't apply for LAI/Depo formulations ---- I know they were wrong but you can not argue with authority figures.

Harold Boxenbaum et. al: Nice to see my former Mentor Late Harold's name in this discussion.....;-);-)
 
dshah
★★  

India,
2023-10-04 13:22
(434 d 01:35 ago)

@ Achievwin
Posting: # 23738
Views: 3,923
 

 Carry-over

Post reply
Hi AchievWin!

❝ <5% of Cmax rule is not applied (this is a news for me)


Any example-Pls give me? As suggested by Helmut- if you are talking about endogenous substance, then the base line correction method would play a significant role.

Honestly, I have seen some carry over- but the protocol does take care of it.
Can you share the protocol's inclusion/exclusion criteria for PK/stat part?

Regards,
Divyen
 
mittyri
★★  

Russia,
2023-10-05 22:15
(432 d 16:43 ago)

@ dshah
Posting: # 23742
Views: 3,919
 

 more than 20% subject carry over effect investigation

Post reply
Dear Divyen!

❝ If more than 20% subject has carry over effect (more than 5%Cmax value), than an investigation would be needed but this indicates that washout period was insufficient.


Could you please enlighten me - why 20%? Why 15% could not trigger investigation? Are 15% not enough to start investigation?
—
Kind regards,
Mittyri
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-10-06 09:08
(432 d 05:50 ago)

@ dshah
Posting: # 23744
Views: 3,834
 

 carry over effect investigation based on what?

Post reply
Hi Divyen,

❝ If more than 20% subject has carry over effect (more than 5%Cmax value), than an investigation would be needed but this indicates that washout period was insufficient.


I agree with what Mittyri wrote above. Is is possible that you mixed it up with the 20% of subjects with extrapolated AUC >20%?
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
dshah
★★  

India,
2023-10-06 15:20
(431 d 23:38 ago)

@ Helmut
Posting: # 23746
Views: 3,771
 

 carry over effect investigation based on what?

Post reply
Hi Helmut & Mittyri!


❝ I agree with what Mittyri wrote above. Is is possible that you mixed it up with the 20% of subjects with extrapolated AUC >20%?


Yes, Probability I may have mixed up the things.
But with carry over effect, there is high probability that the subject would not have ratio of AUCt/AUCinf>0.8? which can be due to insufficient washout period? So there is high chance that where carry over is observed, the AUCt/AUCinf> 0.8 is not achieved and thus the investigation on this.
 
mittyri
★★  

Russia,
2023-10-05 22:34
(432 d 16:23 ago)

@ Achievwin
Posting: # 23743
Views: 3,909
 

 Outdated and wrong answers

Post reply
Dear Achievewin!

15-20 years ago the answers could be the following
  1. How to measure carry-over (any particular PK parameters or in vitro measures?)
    Usually we say that unequal carryover exists, when the p-value for Sequence effect in ANOVA is less than 5% for any of parameters of interest.
    We say that equal carryover exists, when the p-value for Period effect in ANOVA is less than 5%.

  2. How to assess equal or unequal carryover?
    See above

  3. Differences in 1st order or other order carry-over

    Something like this (one carryover effect overrides the previous one)
    https://online.stat.psu.edu/stat509/lesson/15/15.5

  4. Is there a cut-off to call negligible carry-over
    If the sequence effect is more than 5%: the carry-over effect is negligible.

  5. What are the statistical tests to call it a unequal carry-over or no un-equal carry-over.
    ANOVA F test

  6. How to factor or apply any corrections of observed carry-over in BE and RSABE calculations?
    Apply BE for the 1st period only.


Please don't get me wrong. These answers could be correct decades ago.
—
Kind regards,
Mittyri
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-10-06 09:19
(432 d 05:39 ago)

@ mittyri
Posting: # 23745
Views: 3,823
 

 Wrong answer

Post reply
Hi Mittyri & Achievewin,

❝ 15-20 years ago the answers could be the following


Speaking from a regulatory perspective since 23 years (the EMA Guideline) wrong.

❝ 6. How to factor or apply any corrections of observed carry-over in BE and RSABE calculations?

❝ Apply BE for the 1st period only.


Proven to be wrong in 1989.*

  • Freeman PR. The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Stat Med. 1989; 8(12): 1421–32. doi:10.1002/sim.4780081202.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
UA Flag
Activity
 Admin contact
23,336 posts in 4,902 threads, 1,666 registered users;
45 visitors (0 registered, 45 guests [including 9 identified bots]).
Forum time: 13:58 CET (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5